Price
$56.56-24.34%Social Signal Score
Analyst Ratings
33 analystsRevenue
$242.72M+51.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brett Monia
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,480
- Beta
- 0.40
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.20
Financials
Revenue
$242.72M+51.4%Net Income
$-109.97M-525.2%EBITDA
$-97.02M-336.6%Free Cash Flow
$-192.13MEPS (diluted)
$-0.66-414.3%Shares Outstanding (diluted)
166.21M+34.1%Operating Expenses
$370.10MCash & Debt
$1.88BReturn of Capital
$0.00Revenue by Segment (annual)
$836.69MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $944.00M | $-381.00M | $-2.38 |
| 2024 | $705.14M | $-453.90M | $-3.04 |
| 2023 | $787.65M | $-366.29M | $-2.56 |
| 2022 | $587.37M | $-269.72M | $-1.90 |
| 2021 | $810.46M | $-28.60M | $-0.20 |
| 2020 | $729.26M | $-444.26M | $-3.18 |
| 2019 | $1.12B | $278.14M | $2.10 |
| 2018 | $599.67M | $273.74M | $2.07 |
| 2017 | $514.18M | $346.0K | $0.15 |
| 2016 | $372.78M | $-60.40M | $-0.72 |
| 2015 | $283.70M | $-88.28M | $-0.74 |
| 2014 | $214.16M | $-38.98M | $-0.33 |
| 2013 | $147.28M | $-60.64M | $-0.55 |
| 2012 | $102.05M | $-65.48M | $-0.65 |
Valuation
IONShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
40-27.27%Social Signal Score
Mentions (45)
- Newsmarketbeat.com·2d ago·Negative
Ionis Pharmaceuticals Pushes TRYNGOLZA Access as Insurer Requirements Slow Launch Ionis Pharmaceuticals NASDAQ: IONS is working to accelerate prescriptions for TRYNGOLZA as physicians gain experience with the drug and patients navigate insurance requirements, CEO Brett Monia said at the Jefferies Global Healthcare Conference.
View source ↗ - Newszacks.com·4d ago·Neutral
Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia IONS expands Tryngolza's European reach as the EU approves its use for sHTG, marking a first for RNA-targeted therapies in this patient population.
View source ↗ - News (RSS)seekingalpha·4d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies Global Healthcare Conference 2026 Transcript Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsbusinesswire.com·5d ago·Negative
TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). TRYNGOLZA is the first and only RNA-targeted th…
View source ↗ - Newsmarketbeat.com·6d ago·Negative
Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference.
View source ↗ - Newsglobenewswire.com·12d ago·Negative
Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS). Ionis is a commercial and clinical-stage drug company.
View source ↗ - News (RSS)fool·12d ago·Positive
Ionis (IONS) Q3 2026 Earnings Call Transcript Launch ramp slows and cash flow breakeven shifts a year to 2029.
View source ↗ - Newsfool.com·13d ago·Neutral
Ionis: 3 Key Takeaways for Long-Term Investors Ionis lowered 2026 TRYNGOLZA revenue guidance to approximately $50 million. DAWNZERA's third-quarter product sales rose 40% to $37 million.
View source ↗ - Newsseekingalpha.com·13d ago·Negative
…olza Disappointment Ionis Pharmaceuticals, Inc. stock plunged over 25% after Q3 earnings, despite beating revenue and EPS expectations and reaffirming 2026 guidance. IONS slashed 2026 Tryngolza sales guidance by more than half due to slower-than-expected uptake and competitive pressures, undermining previous multi-billion dollar forecasts. Major clinical and commercial setbacks in 2026, including partner trial failures and disappointing Tryngolza launch, have eroded confidence in IONS' transitio…
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Q3 2026 Earnings Call Transcript Ionis Pharmaceuticals, Inc. ( IONS ) Q3 2026 Earnings Call November 9, 2026 9:00 AM EST Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Holly Kordasiewicz - Executive VP & Chief Development Officer Elizabeth L.
View source ↗ - Newsbenzinga.com·13d ago·Negative
Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday? Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance.
View source ↗ - News (RSS)investing·13d ago·Neutral
Why is Ionis Pharmaceuticals stock tumbling today?
View source ↗ - Newsmarketbeat.com·13d ago·Negative
What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call Ionis Pharmaceuticals NASDAQ: IONS lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive cash flow back by a year.
View source ↗ - Newszacks.com·13d ago·Neutral
Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newsbarrons.com·13d ago·Negative
Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.
View source ↗ - News (RSS)seekingalpha·15d ago·Negative
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
View source ↗ - Newszacks.com·17d ago·Neutral
Curious about Ionis Pharmaceuticals (IONS) Q3 Performance? Explore Wall Street Estimates for Key Metrics Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - News (RSS)seekingalpha·28d ago·Positive
Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside
View source ↗ - Newsseekingalpha.com·28d ago·Positive
Ionis Pharmaceuticals: Compelling Long-Term Commercial Upside Ionis Pharmaceuticals, Inc.'s independent launches should increasingly give it more exposure to its commercial successes going forward. For now, partner royalties also provide nice recurring revenues. And TRYNGOLZA's broader indication expands IONS revenue prospects as well. Similarly, DAWNZERA and ZANVASTRO help diversify IONS' pipeline. HIBSAGO also brings more royalty exposure to a different disease market.
View source ↗ - News (Marketaux)gurufocus.com·37d ago·Positive
Ionis Pharmaceuticals (IONS) Gains CHMP Nod for Tryngolza Expansion in Severe Hypertriglyceridemia On October 16, 2026, Ionis [+294 characters]
View source ↗ - Newsbusinesswire.com·37d ago·Neutral
…(olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the indication extension for TRYNGOLZA® (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients wit…
View source ↗ - News (RSS)investing·60d ago·Negative
Ionis, Roche report positive phase 3 data for kidney drug
View source ↗ - News (RSS)fool·63d ago·Neutral
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook Shares of Ionis are down more than 40% so far this year.
View source ↗ - Newsfool.com·63d ago·Neutral
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook Ionis has six commercial therapies, mostly focused on rare diseases. Zanvastro treats Alexander disease, a brain disorder.
View source ↗ - Newsmarketbeat.com·64d ago·Neutral
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks Ionis Pharmaceuticals NASDAQ: IONS CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)finance.yahoo.com·69d ago·Negative
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. Pelacarsen was initially discovered by <[+333 characters]
View source ↗ - News (RSS)seekingalpha·73d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsfool.com·74d ago·Neutral
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. Cathie Wood has bought and sold the stock a lot, so don't follow her blindly. The company posted a loss in its last quarter, but revenue is growing robustly.
View source ↗ - News (RSS)zerohedge·75d ago·Negative
…third quarter and fiscal 2026 results. Herbalife (HLF) rises 7% after the maker of dietary supplements announced a $250 million share buyback. Ionis Pharmaceuticals (IONS) falls 10% and Amgen (AMGN) slumps 5% after Novartis AG said its heart medication, pelacarsen, failed in a final-stage study. Pharvaris (PHVS) soars 25% after a Phase 3 trial of its deucrictibant extended-release tablet for the prevention of hereditary angioedema attacks met its primary and secondary endpoints. Rigetti Computin…
View source ↗ - News (RSS)seekingalpha·75d ago·Neutral
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow
View source ↗ - News (Marketaux)seekingalpha.com·75d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow (NASDAQ:IONS) 2026-09-07 Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow (NASDAQ:IONS) 2026-09-07
View source ↗ - News (RSS)yahoo·79d ago·Negative
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
View source ↗ - News (RSS)seekingalpha·79d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
View source ↗ - Newsseekingalpha.com·79d ago·Positive
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
View source ↗ - Newsmarketbeat.com·79d ago·Negative
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment Ionis Pharmaceuticals NASDAQ: IONS said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene.
View source ↗ - Newszacks.com·79d ago·Negative
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
View source ↗ - Newsbusinesswire.com·80d ago·Negative
… only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affe…
View source ↗ - Newsreuters.com·80d ago·Neutral
US FDA approves Ionis Pharma's therapy to treat rare brain disorder The U.S. FDA on Thursday approved Ionis Pharmaceuticals' therapy to treat a rare disease that affects the brain's white matter, making it the first treatment to get the nod for the genetic disorder.
View source ↗ - Newsfool.com·80d ago·Negative
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone Ionis experienced a double-whammy in July with two clinical setbacks. However, those were partnered programs, with Ionis' financial impact cushioned.
View source ↗ - Newsfool.com·92d ago·Positive
Breakfast News: A Conversation With Ionis CEO Biotech has been hot in 2026. The sector, tracked by the SPDR S&P Biotech ETF, (XBI +1.44%) is up 39% year to date -- beating tech and running even with energy.
View source ↗ - Newsfool.com·100d ago·Neutral
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report.
View source ↗ - Newsbusinesswire.com·106d ago·Negative
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $IONS--IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $-1.36 per share
Typical surprise +36.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.66 vs $-1.23beat
- Wed, Jul 29$-0.69 vs $-1.09beat
- Wed, Apr 29$-0.56 vs $-0.85beat
- Wed, Feb 25$-1.41 vs $-1.24miss
- Wed, Oct 29$-0.61 vs $-1.15beat
- Wed, Jul 30$0.86 vs $0.27beat
Estimates and results for IONS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IONS officers and directors.
- Bought
- $1.2m
- Sold
- $25.9m
3 trades
23 trades
- Hayden Michael Rbought
- Devers Shannon L.sold
- Swayze Ericsold
- Hayden Michael Rbought
- Hayden Michael Rbought
- Bennett C Franksold
- Bennett C Franksold
- Diaz Allene M.sold
74 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Apr 17, 2023 (42d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (24d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jan 3, 2023 (28d later)Buy$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (355d later)Buy$1,001 - $15,000
- Sheldon Whitehousesenate · RI · disclosed Feb 23, 2016 (34d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
